

CD34 antibody [4H11(APG)] (FITC)

Cat. No. GTX18227

Host	Mouse
Clonality	Monoclonal
Isotype	lgG1
Applications	ICC/IF, FCM
Reactivity	Human

References (2)
Package
100 test

Applications

Application Note

Preservative

*Optimal dilutions/concentrations should be determined by the researcher.

15mM Sodium azide

Suggested dilution	Recommended dilution
ICC/IF	Assay dependent
FCM	$20~\mu l$ reagent / $100~\mu l$ of whole blood or 10^6 cells in a suspension
Not tested in other ap	ications.
Product Note	This antibody reacts with Class III epitope on CD34 (Mucosialin). The antibody 4H11[APG] completely blocks binding of

Properties		
Form	Liquid	
Buffer	PBS	

Class II antibody QBEnd10 and Class III antibodies BIRMA K3 and 8G12 on KG1a cell line.

Storage	Store as concentrated solution. Centrifuge briefly prior to opening vial. Store at 4°C. DO NOT FREEZE. Protect from light.
Concentration	Batch dependent (Please refer to the vial label for the specific concentration.)
Immunogen	Permanent human cell line derived from peripheral leucocytes of a patient suffering from chronic myeloid leukaemia.
Purification	Purified by size-exclusion chromatography
Conjugation	Fluorescein isothiocyanate (FITC) Wavelength
	For laboratory research use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.



determine the structure or sequence of the product.



Note

For full product information, images and publications, please visit our <u>website</u>.

Date 2025 / 10 / 28 Page 1 of 2


Purchasers shall not, and agree not to enable third parties to, analyze, copy, reverse engineer or otherwise attempt to

DATA IMAGES



GTX18227 ICC/IF Image

Detection of CD34 in human chronic myeloid leukemia cell line MOLM-7 with anti-human CD34 [4H11[APG]]: PE (GTX18228).



GTX18227 FCM Image

Surface staining of Kg-1a human acute myelogenous leukemia cell line with anti-human CD34 [4H11[APG]] FITC (GTX18227). Total viable cells were used for analysis.



For full product information, images and publications, please visit our website.

Date 2025 / 10 / 28 Page 2 of 2